Ultragenyx Pharmaceutical: what recent returns signal for investors

Ultragenyx Pharmaceutical (RARE) has drawn attention after a roughly 10% gain over the past month, standing out against a flat past 3 months and a roughly 37% decline over the past year.

The recent 10.3% 1 month share price return, alongside a modest 4.9% year to date gain, contrasts with a 37.0% 1 year total shareholder return decline. This suggests short term momentum is improving while longer term holders remain under pressure.

If Ultragenyx’s move has you reassessing your watchlist, it could be a good moment to scan the market for other specialised healthcare names, starting with 33 healthcare AI stocks

With Ultragenyx trading at US$24.77, alongside an intrinsic value estimate implying a significant discount and a price target more than double the current level, the key question is clear: is there genuine upside here or is the market already assuming strong future growth?

Most Popular Narrative: 53% Undervalued

Ultragenyx’s fair value in the most followed narrative sits at $52.45 versus the latest close at $24.77, framing a wide gap that hinges on ambitious growth and margin assumptions.

The accelerating global identification and diagnosis of rare diseases, supported by advancements in genomics and genetic testing, are expanding the addressable patient pool for Ultragenyx's existing and future therapies, which should drive sustained long-term revenue growth.

Curious how a rare disease pipeline, rising margins and faster growth expectations combine to justify that valuation gap? The narrative leans on bold revenue ramps, a profit swing and a premium future earnings multiple to reach its number.

Result: Fair Value of $52.45 (UNDERVALUED)

However, this upside story runs into real tension with ongoing losses of $575.0 million and heavy reliance on timely regulatory wins for key gene therapy programs.

Another way to look at RARE’s valuation

The earlier narrative leans heavily on future cash flows and a discounted cash flow model. Yet today the market is also pricing Ultragenyx at a P/S of 3.6x versus a fair ratio of 1.9x and a peer average of 8.1x. That mix of “cheap vs peers, rich vs fair ratio” raises a simple question: which anchor matters more for you?

Next Steps

With sentiment clearly mixed, both risks and rewards are on the table. It therefore makes sense to move quickly, review the data yourself and weigh the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

Before you move on, take a moment to scan other opportunities across the market so you are not relying on a single story or sector.

• Spot potential bargains early by checking out the screener containing 25 high quality undiscovered gems that may not yet be crowded with attention.
• Strengthen your core holdings by reviewing the solid balance sheet and fundamentals stocks screener (44 results) to see businesses with sturdier financial foundations.
• Dial back risk when you need stability by using the 70 resilient stocks with low risk scores to focus on companies with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.